The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Image Credit: Caroline Ruda/Shutterstock.com A recent JAMA Network Open study investigated the factors associated with discontinuation and subsequent reinitiation of GLP-1 RAs among overweight or ...

Brito, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues estimated the risk for incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1 RAs versus other ...

Source Reference: Etminan M, et al "GLP-1 RAs and nonarteritic anterior ischemic optic neuropathy -- making sense of the data" JAMA Ophthalmol 2025; DOI: 10.1001/jamaophthalmol.2024.6181.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to U.S. Food and Drug Administration ...

Only 34 of 79 websites stated that compounded drugs were not FDA approved; 39 websites did not report adverse effects, warnings. HealthDay News — Websites that sell compounded glucagon-like ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers, including with respect to US Food and Drug Administration ...